Temporary advice for management of oral retinoid medicines during the COVID-19 pandemic

This guidance covers oral isotretinoin, alitretinoin and acitretin, and the use of remote consultations for pregnancy prevention in women of childbearing potential and monitoring for other safety risks in all patients taking these medicines during the COVID-19 pandemic.

SPS commentary:

MHRA guidance on coronavirus (COVID-19) has been updated to include a link to the new temporary advice for management of oral retinoid medicines during the COVID-19 pandemic guidance, in the 'Medicines and COVID-19' section

Medicines and Healthcare products Regulatory Agency